Bristol-Myers Squibb Co (BRM) – aksjekurser og nyheter

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia

Om Bristol-Myers Squibb Co

Administrerende direktørChris Boerner

Ansatte32,5k

Grunnlagt1887

HovedkontorNew York, New York, USA

Sektor-

Nettstedbms.com

Alle verdier i USD	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	12,22 mrd.	12,50 mrd.	11,49 mrd.	12,97 mrd.
Varekostnad	3,31 mrd.	3,51 mrd.	3,41 mrd.	3,71 mrd.
Direkte driftskostnader	3,31 mrd.	3,51 mrd.	3,41 mrd.	3,71 mrd.
Utgifter til forskning og utvikling	2,43 mrd.	2,56 mrd.	2,24 mrd.	2,54 mrd.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	1,79 mrd.	2,09 mrd.	1,61 mrd.	1,82 mrd.
Driftskostnader	5,05 mrd.	5,47 mrd.	4,28 mrd.	4,80 mrd.
Totale driftskostnader	8,36 mrd.	8,98 mrd.	7,69 mrd.	8,51 mrd.
Driftsinntekter	3,86 mrd.	3,52 mrd.	3,80 mrd.	4,46 mrd.
Andre ikke-operasjonelle inntekter	529,00 mill.	544,00 mill.	125,00 mill.	106,00 mill.
EBT inkludert uvanlige elementer	3,11 mrd.	1,47 mrd.	3,24 mrd.	4,09 mrd.
EBT uten uvanlige elementer	4,07 mrd.	3,86 mrd.	3,65 mrd.	4,35 mrd.
Kostnad for inntektsskatt	919,00 mill.	384,00 mill.	561,00 mill.	770,00 mill.
Faktisk avgiftssats	29,51 %	26,12 %	17,32 %	18,84 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	2,20 mrd.	1,09 mrd.	2,68 mrd.	3,32 mrd.
Netto fortjenestemargin	18,01 %	8,69 %	23,30 %	25,57 %
Resultat per aksje	1,63	1,26	1,58	2,04
Rente- og investeringsinntekter	161,00 mill.	148,00 mill.	104,00 mill.	101,00 mill.
Rentekostnader	−482,00 mill.	−432,00 mill.	−406,00 mill.	−403,00 mill.
Netto rentekostnader	−321,00 mill.	−284,00 mill.	−302,00 mill.	−302,00 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	4,91 mrd.	4,54 mrd.	4,41 mrd.	5,08 mrd.
Gevinst eller tap ved salg av eiendeler	−9,00 mill.	-	−34,00 mill.	−142,00 mill.

Finance

Spør om hva som helst